Skip to main content
SpringerLink
Log in

Exemestan in der adjuvanten Therapie des postmenopausalen östrogenrezeptorpositiven Mammakarzinoms

  • Journal Club
  • Published:
Gynäkologische Endokrinologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. ATAC Trialists‘ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131–2139

    Article  PubMed  Google Scholar 

  2. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM (2002) An overview of the pharmacology and pharmacokinetics of the newer generation of aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95:2006–2016

    Article  CAS  PubMed  Google Scholar 

  3. Coombes RC, Hall E, Gibson LJ et al. (2994) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092

    Article  Google Scholar 

  4. Dixon JM (2004) Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert Opin Pharmacother 5:307–316

    Article  CAS  PubMed  Google Scholar 

  5. Goldhirsh A, Wood WC, Gelber RD et al. (2003) Meeting highlights: Updated international expert consensus in the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365

    Article  PubMed  Google Scholar 

  6. Goss PE (2001) Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res 7 [12 Suppl]:4397S–4401S

  7. Goss PE, Ingle JN, Martino S et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802

    Article  CAS  PubMed  Google Scholar 

  8. Kvinnsland S, Anker G, Dirix LY et al. (2000) High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 36:976–982

    Article  CAS  PubMed  Google Scholar 

  9. Paridaens R, Dirix LY, Lohrisch C et al. (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391–1398

    Article  CAS  PubMed  Google Scholar 

  10. Piccart-Gebhart MJ (2004) New stars in the sky of treatment for early breast cancer. N Engl J Med 350:1140–1142

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Frauenklinik der Klinikum Chemnitz gGmbH

    T. Steck

  2. Frauenklinik der Klinikum Chemnitz gGmbH, Flemmingstraße 4, 09116 , Chemnitz

    T. Steck

Authors
  1. T. Steck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Steck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steck, T. Exemestan in der adjuvanten Therapie des postmenopausalen östrogenrezeptorpositiven Mammakarzinoms. Gynäkologische Endokrinologie 2, 169–171 (2004). https://doi.org/10.1007/s10304-004-0072-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-004-0072-7

Search

Navigation